Neurizon Therapeutics Limited has released a press release.
Appendix 4E & Preliminary Final Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Inhibition of SARS-CoV-2 by MPL in Human Respiratory Cells
- Reinstatement to Official Quotation
- Confirmation of Preliminary COVID-19 Results
- Voluntary Suspension
- Virtual Investor Briefing Presentation
Later from Neurizon Therapeutics
- Epichem in partnership to develop waste into fuel technology
- Elanco Option Update
- Monepantel Anti-viral Activity Against SARS-CoV-2 Confirmed
- PharmAust Shareholder Update
- PAA awarded grant for Phase I trial in Motor Neurone Disease
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics